Vancouver, WA – According to filings with the U.S. Securities and Exchange Commission, AbSci is raising $64,999,976.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Sean Mcclain played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AbSci

AbSci is a leading synthetic biology company focused on redefining protein biomanufacturing. We are making protein production as simple as DNA synthesis through our revolutionary Protein Printing technology. AbSci enables a pathway to commercialization for biologics that otherwise wouldn’t get to market due to poor manufacturability. Our mission is to improve patients’ lives by reducing drug costs, accelerating development timelines, and enabling new biologic therapies to market.

To learn more about AbSci, visit http://www.absci.com/

Contact:
Sean Mcclain, President and Chief Executive Officer
360-949-1041
https://www.linkedin.com/in/sean-mcclain/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved